Sign up to save your podcasts
Or
Share Matthew S. Davids, MD, MMSc - Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Matthew S. Davids, MD, MMSc - Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies
Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.
More shows like PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
Lung Cancer Update
32 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
27 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
10 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
Hematologic Oncology Update
72 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
325 Listeners
Journal of Clinical Oncology (JCO) Podcast
38 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
Research To Practice | Oncology Videos
113 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
Exchanges
991 Listeners
ASCO Daily News
58 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
The Clinical Problem Solvers
515 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
169 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
39 Listeners